Arexvy is an RSV vaccine currently authorised in the US and a further 35 countries. Credit: MargJohnsonVA/Shutterstock. GlaxoSmithKline (GSK) has received approval ...

The GSK (LSE:GSK) share price has fallen off its perch. So it may be a good time to research and consider the stock opportunity. I think the global biopharma company has been dripping with promise ...

The GSK share price has tumbled recently on a number of factors, but I think its fundamentals look strong, leaving the stock undervalued right now. When investing, your capital is at risk.

A judge in the U.K. last month sided with Pfizer over GSK in a respiratory syncytial virus vaccine patent lawsuit, positioning both companies to compete for that market and laying down a marker for ...

GSK’s (LSE: GSK) share price is down 28% from its 15 May 12-month traded high of £18.19. As a shareholder, this raises the question of whether I should sell, keep what I have, or buy more. In my ...

A phase 3 trial of GSK’s linerixibat in a liver disease has hit its primary endpoint, keeping the drugmaker on track to launch the first treatment for the relentless itching experienced by some ...

Nov 19 (Reuters) - British drugmaker GSK (GSK.L), opens new tab said on Tuesday its experimental therapy, linerixibat, met its main goal in a late-stage trial to treat patients with a so-called ...

GSK stock remains in a deep bear market, falling by 27% from the year-to-date high. The company made strong progress on its linerixibat trial. There are concerns about Robert Kennedy Jr ...

SINGAPORE - The expansion of British drugmaker GSK’s facility in Tuas has earned the title of Singapore’s largest vaccine production site based on a cumulative investment of some $850 million ...

Simply sign up to the Pharmaceuticals sector myFT Digest -- delivered directly to your inbox. GSK hailed progress for its withdrawn blood cancer drug Blenrep on Thursday, raising the prospect of ...

GSK said its first priority was the staff affected by the move Pharmaceutical firm GlaxoSmithKline (GSK) has confirmed job losses at one of its UK sites. It is believed about 200 roles will be cut ...